BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Roche announces no impact of Omicron variant on cobas, Elecsys assays

06 January 2022 | News

The diagnostic major is taking adequate steps to ensure that the tests are perform as expected



Based on Roche Diagnostics' silico (computer-based) analyses, the cobas SARS-CoV-2 is predicted to detect all variants including the omicron variant (including sub-lineages BA.1 and BA.2). Also, based on the assay design, no impact of the variants including omicron is expected on the Elecsys Anti-SARS-CoV-2 and Elecsys SARS-CoV-2 Antigen assays. As new variant strains emerge, the diagnostic major is taking adequate steps to ensure that our tests perform as expected.

Narendra Varde, MD - Roche Diagnostics India & Neighbouring Markets said, “We continue to monitor the evolution of SARS-CoV-2 variants and remain committed to providing laboratories with high-quality molecular and serology testing solutions that aid in diagnosing affected patients. We have helped build testing infrastructure in the country through the installation of very high-throughput testing instruments in several state medical and ICMR institutions. Our cobas SARS-CoV-2 assay has been used extensively in the country during the pandemic and continues to remain reliable and useful with the emerging Omicron variant.”